Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

How Risky Is Ocugen After Its Recent Setback?

TheMotleyFool

0 0

How Risky Is Ocugen After Its Recent Setback?Photo, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Investors cheered on Ocugen (NASDAQ: OCGN) earlier this year when it signed a deal to co-commercialize Bharat Biotech's vaccine candidate in the U.S. The company recently abandoned the idea of a quick authorization, though. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss what happened -- and what this means for the stock.

Source Fool.com

Like: 0

OCGN

Teilen